Antitumor activity of pan‐ HER inhibitors in HER 2‐positive gastric cancer-Reference-Cited by-同舟云学术

Antitumor activity of pan‐ HER inhibitors in HER 2‐positive gastric cancer

Published:2018-03-25 Issue:4 Volume:109 Page:1166-1176
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Yoshioka Takahiro¹,Shien Kazuhiko²^ORCID,Namba Kei²,Torigoe Hidejiro²,Sato Hiroki²,Tomida Shuta³,Yamamoto Hiromasa²^ORCID,Asano Hiroaki¹,Soh Junichi²,Tsukuda Kazunori¹,Nagasaka Takeshi¹,Fujiwara Toshiyoshi¹,Toyooka Shinichi²^ORCID

Affiliation:

1. Department of Gastroenterological Surgery Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan

2. Department of General Thoracic Surgery, Breast and Endocrinological Surgery Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan

3. Department of Bioinformatics Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.13546

Reference40 articles.

1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

2. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study